Status: Recruiting
Prospective Clinical Evaluation of the BioFire Emerging Coronavirus Panel for the Detection of COVID-19 and Other Coronaviruses
The Biomedical Advanced Research and Development Authority (BARDA) has contracted BioFire Defense (BFDf) to develop the BioFire Emerging Coronavirus (ECoV) Panel, a nucleic acid test capable of detecting coronaviruses from nasopharyngeal swab (NPS) in transport medium. This study aims to evaluate the diagnostic accuracy of the assays comprising the BioFire ECoV Panel. It is hypothesized that the BioFire ECoV Panel assays will be highly sensitive and specific for the detection of the coronaviruses included on the panel.
Participants needed: 1,500
Trial details
Biological sex: AllType: ObservationalSponsor: BioFire Defense LLCUpdated: Oct 27, 2025Locations: 6
Eligibility criteria
Specimen is residual NPS in transport medium (VTM or UTM) left over from standar... [+2]
Specimen is unable to be tested within the defined storage parameters [+2]